Literature DB >> 7310433

Criteria for the diagnosis of the Guillain-Barré syndrome. A critique of the NINCDS guidelines.

C M Poser.   

Abstract

The publication of "official" criteria for the diagnosis of the Guillain-Barré syndrome designed for the purpose of aiding epidemiological studies, has resulted in excluding from consideration a number of fragmentary and atypical cases. Because it is a syndrome and not a disease entity, the limits are arbitrary. Several of the criteria are confusing and contradictory; they ignore a vast amount of literature which clearly documents the variability of the signs and symptoms.

Mesh:

Year:  1981        PMID: 7310433     DOI: 10.1016/0022-510x(81)90004-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Guillain-Barré syndrome following zimeldine treatment.

Authors:  J Fagius; P O Osterman; A Sidén; B E Wiholm
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-01       Impact factor: 10.154

2.  Subacute sensory neuropathy.

Authors:  R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-09       Impact factor: 10.154

3.  The epidemiology of inflammatory polyradiculoneuropathy. A critical review of the distribution, characteristics and outcome of the disease. Plasmapheresis Study Group.

Authors:  E Beghi; F Cornelio; M Marconi; N Rizzuto; P Tonali
Journal:  Ital J Neurol Sci       Date:  1991-02

4.  The doctor as patient: an encounter with Guillain-Bárré syndrome.

Authors:  D Bowes
Journal:  Can Med Assoc J       Date:  1984-12-01       Impact factor: 8.262

5.  Idiopathic inflammatory polyradiculoneuropathy: evaluation of clinical and laboratory data and therapeutic considerations.

Authors:  G Valli; L Ferini Strambi; E Nobile Orazio; G Scarlato
Journal:  Ital J Neurol Sci       Date:  1983-04

6.  Radiculomyelopathy associated with herpes simplex genitalis treated with adenosine arabinoside.

Authors:  C E Handler; G D Perkin; R Fray; J Woinarski
Journal:  Postgrad Med J       Date:  1983-06       Impact factor: 2.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.